Description: American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
Home Page: www.abvcpharma.com
ABVC Technical Analysis
44370 Old Warm Springs Boulevard
Fremont,
CA
94538
United States
Phone:
510 668 0881
Officers
| Name | Title |
|---|---|
| Mr. Eugene Jiang | Chairman & Chief Bus. Officer |
| Dr. Howard Doong M.D., Ph.D. | Pres & CEO |
| Dr. Chi-Hsin King Ph.D. | Chief Scientific Officer |
| Dr. Tsung-Shann Jiang Ph.D. | Chief Strategy Officer, Member of Scientific Advisory Board & Director |
| Mr. Leeds Chow | Chief Financial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.08 |
| Price-to-Sales TTM: | 66.5973 |
| IPO Date: | 2017-10-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 28 |